Clinical Trial Update: Lenalidomide and Low-dose Cyclophosphamide for MALT Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial investigating lenalidomide plus low-dose cyclophosphamide for MALT lymphoma; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Marginal Zone B-cell Lymphoma
• Malt Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• cyclophosphamide (low-dose) (cyclophosphamide)

Snippet

Sponsor: National Taiwan University Hospital | Conditions: Antibiotics-unresponsive MALT Lymphoma, Relapsed MALT Type Extranodal Marginal Zone B-Cell Lymphoma | Phase 2 | Status: UNKNOWN